Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 441

1.

A carbohydrate-reduced high-protein diet acutely decreases postprandial and diurnal glucose excursions in type 2 diabetes patients.

Samkani A, Skytte MJ, Kandel D, Kjaer S, Astrup A, Deacon CF, Holst JJ, Madsbad S, Rehfeld JF, Haugaard SB, Krarup T.

Br J Nutr. 2018 Apr;119(8):910-917. doi: 10.1017/S0007114518000521.

PMID:
29644957
2.

Erratum to semaglutide seems to be more effective the other GLP-1Ras.

Holst JJ, Madsbad S.

Ann Transl Med. 2018 Feb;6(3):74. doi: 10.21037/atm.2018.01.20.

3.

Systems Signatures Reveal Unique Remission-path of Type 2 Diabetes Following Roux-en-Y Gastric Bypass Surgery.

Li QR, Wang ZM, Wewer Albrechtsen NJ, Wang DD, Su ZD, Gao XF, Wu QQ, Zhang HP, Zhu L, Li RX, Jacobsen S, Jørgensen NB, Dirksen C, Bojsen-Møller KN, Petersen JS, Madsbad S, Clausen TR, Diderichsen B, Chen LN, Holst JJ, Zeng R, Wu JR.

EBioMedicine. 2018 Feb;28:234-240. doi: 10.1016/j.ebiom.2018.01.018. Epub 2018 Feb 2.

4.

Effects of Preceding Ethanol Intake on Glucose Response to Low-Dose Glucagon in Individuals With Type 1 Diabetes: A Randomized, Placebo-Controlled, Crossover Study.

Ranjan A, Nørgaard K, Tetzschner R, Steineck IIK, Clausen TR, Holst JJ, Madsbad S, Schmidt S.

Diabetes Care. 2018 Apr;41(4):797-806. doi: 10.2337/dc17-1458. Epub 2018 Jan 22.

PMID:
29358493
5.

Semaglutide seems to be more effective the other GLP-1Ras.

Holst JJ, Madsbad S.

Ann Transl Med. 2017 Dec;5(24):505. doi: 10.21037/atm.2017.11.10. No abstract available. Erratum in: Ann Transl Med. 2018 Feb;6(3):74.

6.

Treatment with liraglutide may improve markers of CVD reflected by reduced levels of apoB.

Engelbrechtsen L, Lundgren J, Wewer Albrechtsen NJ, Mahendran Y, Iepsen EW, Finocchietto P, Jonsson AE, Madsbad S, Holst JJ, Vestergaard H, Hansen T, Torekov SS.

Obes Sci Pract. 2017 Nov 21;3(4):425-433. doi: 10.1002/osp4.133. eCollection 2017 Dec.

7.

Instrumentalization of Eating Improves Weight Loss Maintenance in Obesity.

Christensen BJ, Iepsen EW, Lundgren J, Holm L, Madsbad S, Holst JJ, Torekov SS.

Obes Facts. 2017;10(6):633-647. doi: 10.1159/000481138. Epub 2017 Dec 6.

8.

Circulating Glucagon 1-61 Regulates Blood Glucose by Increasing Insulin Secretion and Hepatic Glucose Production.

Wewer Albrechtsen NJ, Kuhre RE, Hornburg D, Jensen CZ, Hornum M, Dirksen C, Svane M, Gasbjerg LS, Jørgensen NB, Gabe MN, Balk-Møller E, Albrechtsen R, Winther-Sørensen M, Galsgaard KD, Meissner F, Jorsal T, Lund A, Vilsbøll T, Eliasen R, Bojsen-Møller KN, Idorn T, Deacon CF, Knop FK, Rosenkilde MM, Hartmann B, Feldt-Rasmussen B, Mann M, Madsbad S, Holst JJ.

Cell Rep. 2017 Nov 7;21(6):1452-1460. doi: 10.1016/j.celrep.2017.10.034.

9.

Relationship between Optimum Mini-doses of Glucagon and Insulin Levels when Treating Mild Hypoglycaemia in Patients with Type 1 Diabetes - A Simulation Study.

Ranjan A, Wendt SL, Schmidt S, Madsbad S, Holst JJ, Madsen H, Knudsen CB, Jørgensen JB, Nørgaard K.

Basic Clin Pharmacol Toxicol. 2018 Mar;122(3):322-330. doi: 10.1111/bcpt.12907. Epub 2017 Oct 11.

PMID:
28922582
10.

Liraglutide and Renal Outcomes in Type 2 Diabetes.

Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB; LEADER Steering Committee and Investigators.

N Engl J Med. 2017 Aug 31;377(9):839-848. doi: 10.1056/NEJMoa1616011.

11.

S100A8/A9 (Calprotectin), Interleukin-6, and C-Reactive Protein in Obesity and Diabetes before and after Roux-en-Y Gastric Bypass Surgery.

Lylloff L, Bathum L, Madsbad S, Grundtvig JLG, Nordgaard-Lassen I, Fenger M.

Obes Facts. 2017;10(4):386-395. doi: 10.1159/000478097. Epub 2017 Aug 23.

12.

Nutrient re-routing and altered gut-islet cell crosstalk may explain early relief of severe postprandial hypoglycaemia after reversal of Roux-en-Y gastric bypass.

Svane MS, Toft-Nielsen MB, Kristiansen VB, Hartmann B, Holst JJ, Madsbad S, Bojsen-Møller KN.

Diabet Med. 2017 Dec;34(12):1783-1787. doi: 10.1111/dme.13443.

PMID:
28782840
13.

Cross-Validation of a Glucose-Insulin-Glucagon Pharmacodynamics Model for Simulation Using Data From Patients With Type 1 Diabetes.

Wendt SL, Ranjan A, Møller JK, Schmidt S, Knudsen CB, Holst JJ, Madsbad S, Madsen H, Nørgaard K, Jørgensen JB.

J Diabetes Sci Technol. 2017 Nov;11(6):1101-1111. doi: 10.1177/1932296817693254. Epub 2017 Feb 1.

PMID:
28654314
14.

Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials.

von Scholten BJ, Davies MJ, Persson F, Hansen TW, Madsbad S, Endahl L, Jepsen CH, Rossing P.

J Diabetes Complications. 2017 Jul;31(7):1164-1168. doi: 10.1016/j.jdiacomp.2017.04.003. Epub 2017 Apr 11.

PMID:
28462892
15.

A sandwich ELISA for measurement of the primary glucagon-like peptide-1 metabolite.

Wewer Albrechtsen NJ, Asmar A, Jensen F, Törang S, Simonsen L, Kuhre RE, Asmar M, Veedfald S, Plamboeck A, Knop FK, Vilsbøll T, Madsbad S, Nauck MA, Deacon CF, Bülow J, Holst JJ, Hartmann B.

Am J Physiol Endocrinol Metab. 2017 Sep 1;313(3):E284-E291. doi: 10.1152/ajpendo.00005.2017. Epub 2017 Apr 18.

PMID:
28420649
16.

Glycaemic control and weight loss with semaglutide in type 2 diabetes.

Madsbad S, Holst JJ.

Lancet Diabetes Endocrinol. 2017 May;5(5):315-317. doi: 10.1016/S2213-8587(17)30094-3. Epub 2017 Apr 3. No abstract available.

PMID:
28385658
17.

Fixed-ratio combination therapy with GLP-1 receptor agonist liraglutide and insulin degludec in people with type 2 diabetes.

Østergaard L, Frandsen CS, Dejgaard TF, Madsbad S.

Expert Rev Clin Pharmacol. 2017 Jun;10(6):621-632. doi: 10.1080/17512433.2017.1313109. Epub 2017 Apr 11. Review.

PMID:
28349716
18.

Short-term effects of a low carbohydrate diet on glycaemic variables and cardiovascular risk markers in patients with type 1 diabetes: A randomized open-label crossover trial.

Ranjan A, Schmidt S, Damm-Frydenberg C, Holst JJ, Madsbad S, Nørgaard K.

Diabetes Obes Metab. 2017 Oct;19(10):1479-1484. doi: 10.1111/dom.12953. Epub 2017 Jul 10.

PMID:
28345762
19.

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.

le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, Ortiz RV, Wilding JPH, Skjøth TV, Manning LS, Pi-Sunyer X; SCALE Obesity Prediabetes NN8022-1839 Study Group.

Lancet. 2017 Apr 8;389(10077):1399-1409. doi: 10.1016/S0140-6736(17)30069-7. Epub 2017 Feb 23.

PMID:
28237263
20.

Chenodeoxycholic acid stimulates glucagon-like peptide-1 secretion in patients after Roux-en-Y gastric bypass.

Nielsen S, Svane MS, Kuhre RE, Clausen TR, Kristiansen VB, Rehfeld JF, Holst JJ, Madsbad S, Bojsen-Moller KN.

Physiol Rep. 2017 Feb;5(3). pii: e13140. doi: 10.14814/phy2.13140. Epub 2017 Feb 14.

Supplemental Content

Loading ...
Support Center